NEW YORK – Suzhou, China-headquartered Ascentage Pharma said on Tuesday that regulators in China have given it permission to start a Phase IIa trial of the MDM2-p53 inhibitor, dubbed APG-115, for the treatment of relapsed or refractory T-cell prolymphocytic leukemia.
T-PLL is a rare and aggressive leukemia characterized by a mutation in ATM located in the 11q22-23 region in the vast majority of cases. Patients with this disease tend not to respond to available chemotherapies and to live between six and nine months on average after diagnosis.